Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Industry Unites Against Annual Japan Price Cuts

This article was originally published in PharmAsia News

Executive Summary

Major groups representing the foreign innovation-based pharma and medtech industries in Japan have come out in strong united opposition to a proposal to adopt annual, rather than biennial, reimbursement price cuts, warning this could adversely affect investment and the provision of healthcare.

You may also be interested in...



Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel